Literature DB >> 68384

Malignant brain tumours associated with adenylate kinase in cerebrospinal fluid.

G Ronquist, P Ericsson, G Frithz, R Hugosson.   

Abstract

Adenylate-kinase activity was measured in cerebrospinal fluid (C.S.F.) from 35 healthy control subjects and 11 patients with brain tumours, of which 9 were malignant and 2 benign. No adenylate kinase could be detected in C.S.F. from the controls or from the patients with benign brain tumours. The enzyme was consistently found in C.S.F. from patients with malignant brain tumours.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 68384     DOI: 10.1016/s0140-6736(77)91320-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  A unifying model of the cell proliferation emphasizing plasma membrane fluxes.

Authors:  E Cervén
Journal:  Experientia       Date:  1990-10-15

2.  Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis.

Authors:  Adeline S L Ng; Joel Kramer; Alejandro Centurion; Josep Dalmau; Eric Huang; Jennifer A Cotter; Michael D Geschwind
Journal:  J Neuroimmunol       Date:  2015-08-08       Impact factor: 3.478

3.  CSF cyclic AMP and CSF adenylate kinase in cerebral ischaemic infarction.

Authors:  T Büttner; C R Hornig; O Busse; W Dorndorf
Journal:  J Neurol       Date:  1986-10       Impact factor: 4.849

4.  Deoxythymidine-kinase in cerebrospinal fluid: a new potential "marker" for brain tumours.

Authors:  J S Gronowitz; C F Källander; H Hagberg; L Persson
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

5.  Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis.

Authors:  Erdem Tüzün; Jeffrey E Rossi; Steve F Karner; Alejandro F Centurion; Josep Dalmau
Journal:  J Neuroimmunol       Date:  2007-04-25       Impact factor: 3.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.